Drug details

Alecensa (alectinib capsules)

type of Antineoplastic Tyrosine Kinase Inhibitors

Alecensa (alectinib) is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response.

The following drugs are related to Alecensa, either as a replacement or used together:

• Proleukin (aldesleukin for injection)
• Hexalen (altretamine)
• Rybrevant (amivantamab-vmjw for injection)
• Azedra (iobenguane i 131 injection)
• Vegzelma (bevacizumab-adcd injection)
• Casodex (bicalutamide)
• Xeloda (capecitabine)
• Cosela (trilaciclib for injection)
• Cytoxan (cyclophosphamide)
• Vizimpro (dacomitinib)
• Sprycel (dasatinib)
• Marinol (dronabinol capsules)
• Elzonris (tagraxofusp-erzs injection)
• Tarceva (erlotinib)
• Neupogen (filgrastim injection)
• Releuko (filgrastim-ayow injection)
• Iressa (gefitinib)
• Gleevec (imatinib mesylate)
• Jaypirca (pirtobrutinib tablets)
• Tykerb (lapatinib)
• Vitrakvi (larotrectinib capsules)
• Lorbrena (lorlatinib tablets)
• Lumakras (sotorasib tablets)
• Zepzelca (lurbinectedin for injection)
• Poteligeo (mogamulizumab-kpkc injection)
• Turalio (pexidartinib capsules)
• Tepmetko (tepotinib tablets)